Attachment II - Page 1 
HUMAN GENE TRANSFER PROTOCOLS 
8810-001* 
9007-002*-‘’ 
9007-003* 
9102-004* 
9105-005* 
9105-006* 
9105-007* 
9105-008 
9105-009* 
91104)10* 
9110-011 
(M) 
CD 
CD 
(M) 
(M) 
(M) 
(M) 
(M) 
(M) 
CD 
CD 
Roficnbeig, Steven A., National Institutes of Health, Bethesda, Maryland; The Treatment of Patients with Advanced Cancer Using 
Cyclophosphamide, InterieuJdn-2 and Tumor Irfiltrating Lymphocytes. 
RAC Approval: 10-3-88/NIH Approval: 3-2-89 
Minor Modification: 3-30-90 
Blaese, R Michael, National Institutes of Health, Bethesda, Maryland; Treatment of Severe Combined Immune Deficiency (SCID) due 
to Adenosine Deaminase (ADA) Deficiency with CD34(+) Selected Autologous Hematopoietic Stem Celis 
RAC Approval: 7-31-90/NIH Approval: 9-6-90 
Major Amendment/RAC Approval: 2-10-92 
Major Amendment/NIH Approval: 4-22-92 
Minor Modification: 4-21-^ 
Minor Modification: 6-7-93 
Rosenberg, Steven A, National Institutes of Health, Bethesda, Maryland; Gene Therapy of Patients with Advanced Cancer Using 
Tumor Infiltrating Lymphocytes Transduced with the Gene Coding for Tumor Necrosis Factor. 
RAC Approval: 7-31-90/NIH Approval: 9-6-90 
Minor Modification: 2-17-94 
Brenner, Malcolm K.; Mirro, Joseph; Hurwitz, Craig; Santana, Victor; and Ihle, James, St. Jude Children’s Research Hospital, 
Memphis, Tennessee; Autologous Bone Marrow Transplant for Children with Acute Myelogenous Leukemia in First Complete Remission; 
Use of Marker Genes to Investigate the Biology of Marrow Reconstitution and the Mechanism of Relapse. 
RAC Approval: 2-4-91/NIH Approval: 7-12-91 
Minor Modification: 11-91 
Brenner, Malcolm K.; Mirro, Joseph; Santana, Victor, and Ihle, James, St. Jude Children’s Research Hospital, Memphis, Teimessee; 
A Phase I/n Trial of High Dose Carboplatin and Etoposide with Autologous Marrow Support for Treatment of Stage D Neuroblastoma in 
First Remission: Use of Marker Genes to Investigate the Biology of Marrow Reconstitution and the Mechanism of Relapse. 
RAC Approval: 5-31-91/NlH Approval: 7-12-91 
Minor Modification: 11-91 
Brenner, Malcolm K.; Mirro, Joseph; Santana, Victor, and Ihle, James, St. Jude Qiildren’s Research Hospital, Memphis, Tennessee; I 
A Phase II Trial of High-Dose Carboplatin and Etoposide with Autologous Marrow Support for Treatment of Relapse /Refractory \ 
Neuroblastoma Without Apparent Bone Marrow Involvement. | 
RAC Approval: 5-31-91/NIH Approval: 7-12-91 1^ 
Minor Modification: 11-91 f 
I 
Deisseroth, Albert B., M.D. Anderson Cancer Research Center, Houston, Texas; Autologous Bone Marrow Transplantation for 
Chronic Myelogenous Leukemia in which Retroviral Markers are Used to Discriminate between Relapse which Arises firm Systemic | { 
Disease Remaining after Preparative Therapy Versus Relapse due to Residual Leukemic Cells in Autologous Marrow; A Pilot Trial. r 
RAC Approval: 5-31-91/NlH Approval: 7-12-91 
Minor Modification: 4-19-93 j 
Ledley, Fred D.; Woo, Savio; Ferry, George; and Hartwell, Whigennand, Baylor College of Medicine, Houston, Texas; I 
Hepatocellular Transplaruation in Acute Hepatic Failure and Targeting Genetic Markers to Hepatic Cells. 
RAC Approval: 5-30-91/NIH Approval: 7-12-91 I 
Lotze, Michael T., University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania; The Administration of Iruerleukin-2 and 
Tumor Infiltrating Lymphocytes to Patients with Melanoma. jn 
RAC Approval: 5-30-91/NIH Approval: 1-17-92 ! 
Minor Modification: 11-30-92 
Rosenberg, Steven A, National Institutes of Health, Bethesda, Maryland; Immunization of Cancer Patients Using Autologous Cancer ' 
Cells Modified by Insertion of the Gene for Tumor Necrosis Factor (INF). 
RAC Approval: 10-7-91/NIH Approval: 10-15-91 i 
Minor Modification: 7-9-92 f 
Rosenberg, Steven A., National Institutes of Health, Bethesda, Maryland; Immunization of Cancer Patients Using Autologous Cancer | 
Cells Modified by Insertion of the Gene for Interleukin-2 (IL-2). 
RAC Approval: 10-7-91/NIH Approval: 10-15-91 5 
[72] 
Recombinant DNA Research, Volume 19 
